Arianna Giacomini

Brescia, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 57 publications

A PTX3/TLR4 axis sustains SHH-Medulloblastoma growth and defines a new therapeutic vulnerability.

A PTX3/TLR4 axis sustains SHH-Medulloblastoma growth and defines a new therapeutic vulnerability.

Journal: Neuro-oncology
Published: December 03, 2025

Corrigendum to "FGF/FGFR inhibitors downmodulate c-Myc oncoprotein and hamper the growth of adrenocortical carcinoma" [Biomed. Pharmacother. 192 (2025) 118677].

Corrigendum to "FGF/FGFR inhibitors downmodulate c-Myc oncoprotein and hamper the growth of adrenocortical carcinoma" [Biomed. Pharmacother. 192 (2025) 118677].

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: November 23, 2025

FGF/FGFR inhibitors downmodulates c-Myc oncoprotein and hampers the growth of adrenocortical carcinoma.

FGF/FGFR inhibitors downmodulates c-Myc oncoprotein and hampers the growth of adrenocortical carcinoma.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 18, 2025

An ureido-substituted benzenesulfonamide carbonic anhydrase inhibitor exerts a potent antitumor effect in vitro and in vivo.

An ureido-substituted benzenesulfonamide carbonic anhydrase inhibitor exerts a potent antitumor effect in vitro and in vivo.

Journal: Experimental hematology & oncology
Published: March 19, 2025

The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.

The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.

Journal: Journal of experimental & clinical cancer research : CR
Published: August 19, 2024

Turn-Adopting Peptidomimetic as a Formyl Peptide Receptor-1 Antagonist.

Turn-Adopting Peptidomimetic as a Formyl Peptide Receptor-1 Antagonist.

Journal: ACS pharmacology & translational science
Published: June 15, 2024

Discovery of novel FGF trap small molecules endowed with anti-myeloma activity.

Discovery of novel FGF trap small molecules endowed with anti-myeloma activity.

Journal: Pharmacological research
Published: December 20, 2023

Proteasome inhibitors as anticancer agents.

Proteasome inhibitors as anticancer agents.

Journal: Expert opinion on therapeutic patents
Published: October 17, 2023

The PTX3/TLR4 autocrine loop as a novel therapeutic target in triple negative breast cancer.

The PTX3/TLR4 autocrine loop as a novel therapeutic target in triple negative breast cancer.

Journal: Experimental hematology & oncology
Published: March 16, 2023

Iron supplementation enhances RSL3-induced ferroptosis to treat naïve and prevent castration-resistant prostate cancer.

Iron supplementation enhances RSL3-induced ferroptosis to treat naïve and prevent castration-resistant prostate cancer.

Journal: Cell death discovery
Published: January 18, 2023

Cannabidiol alters mitochondrial bioenergetics via VDAC1 and triggers cell death in hormone-refractory prostate cancer.

Cannabidiol alters mitochondrial bioenergetics via VDAC1 and triggers cell death in hormone-refractory prostate cancer.

Journal: Pharmacological research
Published: October 24, 2022

FGF-trapping hampers cancer stem-like cells in uveal melanoma.

FGF-trapping hampers cancer stem-like cells in uveal melanoma.

Journal: Cancer cell international
Published: October 07, 2022
Showing 1-12 of 57

Last Updated: 09/26/2026